Market Research Logo

Kancera AB - Product Pipeline Review - 2016

Kancera AB - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Kancera AB - Product Pipeline Review - 2016’, provides an overview of the Kancera AB’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kancera AB, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Kancera AB
  • The report provides overview of Kancera AB including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Kancera AB’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Kancera AB’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Kancera AB’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Kancera AB
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Kancera AB’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Kancera AB Snapshot
Kancera AB Overview
Key Information
Key Facts
Kancera AB - Research and Development Overview
Key Therapeutic Areas
Kancera AB - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Kancera AB - Pipeline Products Glance
Kancera AB - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Kancera AB - Drug Profiles
KAN-0437757
Product Description
Mechanism of Action
R&D Progress
KAN-0438757
Product Description
Mechanism of Action
R&D Progress
KAN-0439834
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Target ROR-1 for Chronic Lymphocytic Leukemia and Melanoma
Product Description
Mechanism of Action
R&D Progress
KAN-0439221
Product Description
Mechanism of Action
R&D Progress
KAN-043936
Product Description
Mechanism of Action
R&D Progress
KAN-0439363
Product Description
Mechanism of Action
R&D Progress
KAN-0439365
Product Description
Mechanism of Action
R&D Progress
KAN-0439828
Product Description
Mechanism of Action
R&D Progress
KAN-0439829
Product Description
Mechanism of Action
R&D Progress
KAN-439782
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Malaria
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Schistosomiasis
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Oncology
Product Description
Mechanism of Action
R&D Progress
Kancera AB - Pipeline Analysis
Kancera AB - Pipeline Products by Target
Kancera AB - Pipeline Products by Route of Administration
Kancera AB - Pipeline Products by Molecule Type
Kancera AB - Pipeline Products by Mechanism of Action
Kancera AB - Recent Pipeline Updates
Kancera AB - Dormant Projects
Kancera AB - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Small Molecules To Agonize GPR-119 For Type 2 Diabetes
Small Molecules To Inhibit SCD1 For Obesity And Diabetes
Kancera AB - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Kancera AB, Key Information
Kancera AB, Key Facts
Kancera AB - Pipeline by Indication, 2016
Kancera AB - Pipeline by Stage of Development, 2016
Kancera AB - Monotherapy Products in Pipeline, 2016
Kancera AB - Partnered Products in Pipeline, 2016
Kancera AB - Partnered Products/ Combination Treatment Modalities, 2016
Kancera AB - Preclinical, 2016
Kancera AB - Discovery, 2016
Kancera AB - Pipeline by Target, 2016
Kancera AB - Pipeline by Route of Administration, 2016
Kancera AB - Pipeline by Molecule Type, 2016
Kancera AB - Pipeline Products by Mechanism of Action, 2016
Kancera AB - Recent Pipeline Updates, 2016
Kancera AB - Dormant Developmental Projects,2016
Kancera AB - Discontinued Pipeline Products, 2016
List of Figures
Kancera AB - Pipeline by Top 10 Indication, 2016
Kancera AB - Pipeline by Stage of Development, 2016
Kancera AB - Monotherapy Products in Pipeline, 2016
Kancera AB - Pipeline by Target, 2016
Kancera AB - Pipeline by Molecule Type, 2016
Kancera AB - Pipeline Products by Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report